P-01 Hereditary angioedema with normal C1-INH and PLG muta-tion treated with tranexamic acid: Beware of the risk of thrombosis Alexis Bocquet, David Launay, Isabelle Boccon-Gibod, Aurlie Du-Thanh, Delphiine Gobert, Sbastien Sanges, Laurence Bouillet Launay &Sanges University of Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000, INSERM, and the Department of Internal Medicine and Clinical Immunology, CHU Lille, National Reference Center for Angioedema (CREAK), Lille, France Allergy, Asthma & Clinical Immunology 2025, 21(Suppl 2) :P-01 Introduction: The anti-fibrinolytic, tranexamic acid (TA) can be proposed as a long term prophylaxis for hereditary angioedema (HAE), and seems to be specifically efficient for HAE with plasminogen gene mutation (HAE-PLG), a subset of HAE with normal C1-INH (HAE-nC1-INH)
The nutrient displacement theory suggests that the displacement of protective anti-inflammatory lipids, such as omega-3 PUFAs (docosahexaenoic acid, EPA), contributes to increased inflammatory signaling via the disinhibition of phospholipase A2, which normally mediates the production of pro-inflammatory mediators (117)
Some peptides may be compounded and prescribed based on individual clinical indication
Medvi integrates comprehensive clinical oversight, behavioral coaching, and flat cash-pay pricing, appealing to patients seeking multidisciplinary support
